ClinicalTrials.govpublic full text
Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers
mmr-d/msi-h colorectal cancers, parp inhibitor, mre11 deficiency, immune checkpoint inhibitor, homologous recombination defect, hrd, msi-h/mmr-d colorectal cancer, niraparib, dostarlimab, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 872895
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.